Pramlintide vs Cagrilintide
How they differ
- FDA status. Pramlintide: FDA-approved as Symlin.1,2 Cagrilintide: In clinical trials; not FDA-approved.3,4,5
Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.
Side by side
| Topic | Pramlintide | Cagrilintide |
|---|---|---|
| What it is | An amylin analogue. The label states that it slows stomach emptying, reduces the rise in glucagon after meals and affects appetite.1 | An investigational long-acting amylin analogue from Novo Nordisk, also known as AM833.3,6 |
| FDA status | FDA-approved FDA-approved. Drugs@FDA lists Symlin with an original approval date of March 16, 2005. The label carries a boxed warning about severe low blood sugar when used with insulin.1,2 | In clinical trials In clinical trials; not FDA-approved3,4,5 Not FDA-approved. FDA states that cagrilintide is not a component of an FDA-approved drug and cannot be used in compounding under federal law.5 |
| HHS compounding policy, October 30, 2026 | Not among the six peptides the policy lists.7 | Not among the six peptides the policy lists.7 |
| FDA compounding safety-risk page | Not addressed in this profile’s sources. | Not addressed in this profile’s sources. |
| Kinds of studies cited |
|
|
| Records collected | 5 ClinicalTrials.gov records and 48 PubMed records collected | |
| Area of study | ||
| Latest dated events |
|
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Citations
Sources
Numbered markers in the text point here. Each link opens the original public record.
- 1SYMLINPEN (pramlintide acetate) injection · SPL version 18 · published 2024-08-20 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026
- 2Drugs@FDA application NDA021332 · original submission status AP · 2005-03-16 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 3Cagrilintide and CagriSema in Children and Adolescents With Excess Body Weight · record history version 5 · last update posted 2026-07-17 ↗
ClinicalTrials.gov · Official source · Source checked July 22, 2026
- 4ClinicalTrials.gov record NCT07220759 · retained source version 2026-08-03:50fb10a6adbd81022c8cc1ee950e283b46f97533acbf5a944399ee4e77eaceb1 ↗
ClinicalTrials.gov · Official source · Source checked August 14, 2026
- 5FDA’s concerns with unapproved GLP-1 drugs used for weight loss · content current as of October 1, 2026 ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 6Once-weekly cagrilintide for weight management in people with overweight and obesity: a dose-finding phase 2 trial (2021) · PMID 34798060 ↗
The Lancet · Official source · Source checked November 14, 2026
- 7HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
- 8Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1, 2025) · PMID 40544433 ↗
The New England Journal of Medicine · Official source · Source checked November 14, 2026
- 9ClinicalTrials.gov record NCT07745504 · retained source version 2026-08-04:624035118e08abe47d4c56faae694b0047f077f295c17f9043520d41dcfc3f70 ↗
ClinicalTrials.gov · Official source · Source checked August 14, 2026